Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib for advanced or unresectable soft tissue sarcoma after failure of antiangiogenic therapy or chemotherapy
ChiCTR2500109087Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib in soft tissue sarcoma (STS), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-Free Survival. Started Sep 2025; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2500109087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109087.